ADDIA SIGNED
Validation of a fast and simple peripheral blood diagnostic biomarker kit for Alzheimer’s disease
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ADDIA project word cloud
Explore the words cloud of the ADDIA project. It provides you a very rough idea of what is the project "ADDIA" about.
Project "ADDIA" data sheet
The following table provides information about the project.
| Coordinator |
AMONETA DIAGNOSTICS
Organization address contact info |
| Coordinator Country | France [FR] |
| Project website | http://www.addia-project-h2020.eu |
| Total cost | 4˙998˙625 € |
| EC max contribution | 4˙998˙625 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-2-2014 |
| Funding Scheme | SME-2 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-08-01 to 2019-07-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | AMONETA DIAGNOSTICS | FR (HUNINGUE) | coordinator | 4˙998˙625.00 |
Map
Project objective
The French SME Amoneta Diagnostics has previously developed a diagnostic kit for Alzheimer’s disease (AD) based on two blood biomarkers that are scientifically proven to be associated with AD. The company holds the intellectual property for specific fluorescent probes that can detect these biomarkers in small amounts of blood using flow cytometry. Currently, no single test to diagnose AD exists. A potential AD diagnosis is usually given by a combination of clinical examination, neuropsychological tests and brain imaging over weeks/months. A lumbar puncture can be performed to detect biomarkers in cerebrospinal fluid, but this procedure is risky and expensive. A definite AD diagnosis can formally only be given by autopsy. Consequently, the diagnosis is assessed late and still questionable. The novel kit allows the diagnosis of AD, using only one single test, in a fast, non-invasive and inexpensive way. We expect the blood-based biomarker kit to facilitate assessment of drug efficacy in AD drug development and the monitoring of treatment efficacy in AD patients. This kit will meet the urgent medical need of ~2 million patients in Europe, Japan and America, that are annually diagnosed with AD. Successful implementation will have a strong impact on the quality of life of patients and a significant impact on the healthcare system and economy. In this project, Amoneta Diagnostics will validate this diagnostic test by performing a Proof-of-Performance (PoP) clinical study in 800 human subjects including 400 AD patients. At the end of this 3-year project, a validated and CE registered IVD biomarker assay will be available and ready for clinical application. This innovative ADDIA biomarker assay will be ready for initial market introduction and further commercialization and implementation. The project is supported by patient organisation Alzheimer Europe, and several leading European Alzheimer centres that are committed to enrol subjects for the PoP clinical study.
Deliverables
| Scientific papers prepared for peer-reviewed open access journals | Documents, reports | 2019-11-11 10:17:23 |
| Letters and project updates to patient organisation Alzheimer Europe | Documents, reports | 2019-11-11 10:17:23 |
Take a look to the deliverables list in detail: detailed list of ADDIA deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Bruno Dubois, MD, PhD, Professor, Jean-Christophe Bier, MD, Frederic Blanc, MD, PhD, Renaud
David, MD, PhD, Jean-François Démonet, MD, PhD, Hüseyin Firat, MD, PhD, Giovanni B Frisoni,
Prof, PhD, MD, Audrey Gabelle, MD, PhD, Hakan I. Gurvit, MD, Adrian Ivanoiu, MD, PhD, Eloi
Magnin, MD, PhD, Moira Marizzoni, PhD, Saliha Moussaoui, PhD, Florence Pasquier, MD
PhD and François Sellal, MD Addia, a Multi- Center Clinical Study of Proof-of-Performance to Validate Blood-BasedBiomarkers for the Diagnostic of Alzheimer’s Disease (AD): The Study Protocol. published pages: , ISSN: , DOI: |
2019-08-29 | |
| 2019 |
F. Blanc, F. Giovanni, M. Marizzoni, C. Mutter, J.C. Bier, F. Sellal, J.F. Démonet, S. Boutillier, H. Firat, S. Moussaoui, R. David, A. Ivanoiu, E. Magnin, A. Gabelle, F. Pasquier, H. Gurvit, B. Dubois ADDIA Chronobiology Study and Proof-of-Performance Study to Validate Blood-Based Biomarkers for the Diagnostic of early Alzheimer’s Disease (AD) published pages: , ISSN: , DOI: |
2019-08-29 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADDIA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ADDIA" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.1.3.)
TT4CL (2019)
Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis
Read MoreHELP (2019)
Collaboration for innovation: Establishment of a pan-nematode drug development platform
Read MoreMISTRAL (2020)
Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination
Read More